ACRS - Aclaris Therapeutics Inc Stock Price, Fair Value and News

$1.15+0.02 (+1.77%)

Delayed as of 22 Apr 2025, 11:58 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ACRS Price Action

Last 7 days

-5.1%

Last 30 days

-30%

Last 90 days

-56.9%

Trailing 12 Months

-9.7%

ACRS RSI Chart

ACRS Valuation

Market Cap

121.9M

Price/Earnings (Trailing)

-0.92

Price/Sales (Trailing)

6.51

EV/EBITDA

-0.74

Price/Free Cashflow

-6.04

ACRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

18.7M

Rev. Growth (Yr)

-47.58%

Rev. Growth (Qtr)

111.93%

ACRS Earnings

Earnings (TTM)

-132.1M

Earnings Growth (Yr)

-6.4K%

Earnings Growth (Qtr)

-1.2K%

ACRS Profitability

Operating Margin

85.09%

EBT Margin

-705.46%

Return on Equity

-84.9%

Return on Assets

-59.94%

Free Cashflow Yield

-16.56%

ACRS Investor Care

Shares Dilution (1Y)

52.16%

Diluted EPS (TTM)

-1.71

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	31.1M	32.0M	27.1M	18.7M
2023	30.8M	31.2M	21.4M	31.2M
2022	6.4M	6.1M	23.5M	29.8M
2021	6.9M	6.6M	6.8M	6.8M
2020	4.4M	5.5M	6.0M	6.5M
2019	9.7M	6.9M	6.8M	4.2M
2018	2.9M	6.5M	6.9M	9.6M
2017	0	0	941.5K	1.8M
2015	25.0K	51.3K	77.7K	104.0K
2014	19.3K	0	17.7K	16.0K
2013	0	0	0	21.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

CEO	Dr. Douglas J. Manion Frcp(C), M.D.
WEBSITE	aclaristx.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	100

Aclaris Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aclaris Therapeutics Inc? What does ACRS stand for in stocks?

ACRS is the stock ticker symbol of Aclaris Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aclaris Therapeutics Inc (ACRS)?

As of Mon Apr 21 2025, market cap of Aclaris Therapeutics Inc is 121.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACRS stock?

You can check ACRS's fair value in chart for subscribers.

Is Aclaris Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACRS is over valued or under valued. Whether Aclaris Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aclaris Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRS.

What is Aclaris Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 21 2025, ACRS's PE ratio (Price to Earnings) is -0.92 and Price to Sales (PS) ratio is 6.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRS PE ratio will change depending on the future growth rate expectations of investors.